| EN
Simcere Pharmaceutical Group Limited(2096.HK) is rapidly transitioning to an innovation and R&D-driven pharmaceutical company, with a mission of “providing today’s patients with medicines of the future.” It has established the State Key Laboratory of Translational Medicine and Innovative Drug Development. Simcere focuses on three therapeutic areas: oncology, central nervous system diseases and autoimmune diseases, with a diversified product portfolio and industry-leading capabilities. Its vigorous in-house R&D efforts and extensive R&D collaborations have made it a strategic cooperation partner with world leading pharmaceutical companies and biotechnology companies, in an effort to bring more global life science breakthroughs to China. We have been continuously recognized as one of the “Top 10 Innovative Pharmaceutical Enterprises in China” and “Top 100 Pharmaceutical Manufacturing Enterprises of China ”.

Milestones

  • 1995

  • 2001

  • 2003

  • 2007

  • 2015

  • 2018

  • 2019

  • 2020

  • Established Jiangsu Simcere, engaging in the sales, marketing and distribution of pharmaceuticals

  • Acquired a controlling interest in Hainan Simcere and manufacturing capabilities of pharmaceuticals, started to build our own research and development team

  • Acquired the entire equity interest in former Simcere Dongyuan, which further enriched our product portfolio and production capabilities

  • Was listed on the NYSE on April 20, 2007, making us the first bio and chemical pharmaceutical company in China to be listed on the NYSE. Simcere completed its privatization in 2013

  • The Ministry of Science and Technology approved the establishment of the State Key Laboratory of Translational Medicine and Innovative Drug Development

  • Shanghai R&D center established

  • Boston R&D Center established

  • Listed on the Hong Kong Stock Exchange (02096.HK)

  • Established Jiangsu Simcere, engaging in the sales, marketing and distribution of pharmaceuticals
  • Acquired a controlling interest in Hainan Simcere and manufacturing capabilities of pharmaceuticals, started to build our own research and development team
  • Acquired the entire equity interest in former Simcere Dongyuan, which further enriched our product portfolio and production capabilities
  • Was listed on the NYSE on April 20, 2007, making us the first bio and chemical pharmaceutical company in China to be listed on the NYSE. Simcere completed its privatization in 2013
  • The Ministry of Science and Technology approved the establishment of the State Key Laboratory of Translational Medicine and Innovative Drug Development
  • Shanghai R&D center established
  • Boston R&D Center established
  • Listed on the Hong Kong Stock Exchange (02096.HK)

Management Team

Mission

Providing Today’s Patients with Medicines of the Future

Core Values

Integrity
Excellence
Perseverance
Proactivity
Customer-First

Simcere CI

  • The name “Simcere” comes from the word “sincere”, which embodies our main principle of treating people with sincerity.
  • On the left side of our logo is Simcerer running against the wind, representing the spirit of unremitting endeavor and the encourage to pursue excellence.
  • The color green symbolizes life, health and vitality.